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Case Report
Delirium due to Scopolamine Patch in 
a 4-Year-Old Boy
Yang-Guang Lin,1,2 Po-Hon Chen,1,3 Fang-Yuan Chang,1,3 Li-Te Wu,1 Kuo-Yu Liao,1,3 Tzee-Chung Wu1,3*
The scopolamine patch is usually used to reduce postoperative nausea and vomiting associated with anes-
thesia and/or surgery. It is also commonly used for the prevention of motion sickness. Transdermal scopol-
amine patches have been used for decades and there are few reports in the literature of toxic psychosis
associated with the product. Most documented cases of acute psychosis following administration of
scopolamine or other anticholinergic agents have been from the adult population. Here we present a 
4-year-old boy with deteriorated cognitive function and changed mental status acutely. Besides flushing
skin and psychotic behaviors including bizarre actions, hallucinations, aggressive behavior, hyperactivity,
and incoherent speech were also noticed. Symptoms and signs were resolved after removal of scopol-
amine patch and conservative management. This case is possibly one of the youngest patients to exhibit
such toxic effects. We hope to relay information about common agents with anticholinergic effects to clinical
practitioners and remind that drug-induced psychosis should be considered in children with acute changes
in behavior.
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Scopolamine patches are mostly prescribed in
adult patients to reduce postoperative nausea and
vomiting (PONV) associated with anesthesia
and surgery. They are also used in surgical patients
for mild analgesic and sedating effects. Delirium
or mental confusion can occur after application of
scopolamine patch. However, predisposing factors
for scopolamine-induced delirium are not known.
Most of these cases have been reported in the
adult population, especially in the elderly. To our
best of knowledge, this case is the youngest toxic
report.
Case Report
A 4-year-old boy exhibiting cognitive deteriora-
tion was presented to the emergency room in 
a dissociative mental state. The symptoms had
been developed over the previous 8 hours, with
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featured bizarre behavior (he perceived his finger
as a pencil and asked his mother to sharpen it),
hallucinations (pointed out nonexistent objects;
grasping or picking at imaginary objects), aggres-
sive behavior (banging his head against the wall),
hyperactivity, and incoherent speech.
Upon arrival at the emergency department,
the boy was incoherent and hyperactive and was
held still by his father. Flushing skin was noted
all over his body, especially in the head and neck
region. His presenting vital signs were as follows:
body temperature, 38.1°C; heart rate, 112 beats/
min; respiratory rate, 20 breaths/min; and blood
pressure, 104/74 mmHg. Physical examination
revealed mildly dilated pupils with normal light
reflex and generalized skin erythema which was
hot to touch, particularly in the head and neck
region. The cognitive deficits were quite remark-
able because he was not oriented to place or time
and was unable to recognize previously familiar
people. Besides urinary retention, no focal neu-
rological abnormalities were noted. There was no
history of head trauma, and no definitive injuries
were identified. Two dime-sized patches were
found behind both ears. His parents said that
these patches were placed by the patient’s grand-
mother 1 day before to prevent motion sickness
from an upcoming long-distance journey. Each
patch contained 1.5 mg of scopolamine.
The patient’s mother provided a past medical
history of the boy, which is significant for allergic
rhinitis and the patient was not taking any prescrip-
tion medications at that time. The grandmother
replaced the applied scopolamine patches on next
day, presuming that there would be an enhanced
effect of preventing motion sickness. Laboratory
results for serum sodium, potassium, chloride,
blood urea nitrogen, creatinine, alanine amino-
transferase, aspartate aminotransferase, sodium
bicarbonate, creatine kinase, creatine kinase-MB,
glucose, magnesium, free calcium, and C-reactive
protein were within normal limits. The hemoglo-
bin concentration was 12.9 g/dL and the leuko-
cyte count 12 × 109/L, with 80.2% segment form
of neutrophils. The drug screen was negative for
salicylates, methanol, amphetamine, cocaine,
cannabinoids, benzodiazepine, opiates, or phen-
cyclidine. The chest X-ray was normal. Due to his
bizarre behavior and suspicion of scopolamine in-
toxication, he was admitted for further evaluation.
Removal of the patches with conservative treatment
was initiated, and toxicologist was consulted.
That evening after admission the patient was
still hyperactive and he was given chloral hydrate
per rectal to promote sleep. The skin rash faded
gradually after removal of the patches and the fever
subsided. However, his mother reported that the
patient complained of dizziness and blurred vision.
On the next day, the patient’s vital signs were
stable but he was still hyperactive. Speech im-
proved and became coherent but he still had dif-
ficulty in initiating sentences. He continued to
complain about blurred vision and dizziness so we
consulted an ophthalmologist. No definitive cause
of blurred vision was found due to lack of patient
cooperation for the visual acuity tests.
On the third day, he became relatively improved
compared to the previous 2 days but his mother
found that he still had memory deficits, including
difficulty in recognizing a close neighbor and in-
completely singing a familiar Taiwanese children’s
song. Fortunately, he continued to improve and
was discharged on Day 4 to outpatient treatment.
He was completely recovered 2 days later.
Discussion
Delirium is characterized as rapid onset of changes
in mental status and loss of memory. This disease
has various synonyms, including encephalopathy,
acute organic brain syndrome, acute confusional
state, and, less commonly, acute toxic psychosis.
Clinical manifestations of delirium include con-
fusion, memory loss, disorientation to time and
space, delusions and hallucinations, and incoher-
ent speech.1 Occasionally, the symptoms fluctuate
over time. The cause for delirium is thought to be a
global disturbance in cerebral cortex functioning
sparing the cerebellum.2 Excessive neurotransmitter
release and abnormal signal transduction are
thought to be the mechanisms for delirium.3
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Overactivity of muscarinic receptors in the reticular
activating system which is located in the cerebral
cortex and hippocampus, may cause disturbances
to cognition and thereby contribute to typical
manifestations of delirium.
Scopolamine patches are mostly prescribed in
adult patients to reduce postoperative nausea and
vomiting (PONV) associated with anesthesia
and surgery. They also have mild analgesic and
sedating effects for some surgical patients. The
transdermal scopolamine may also be used to re-
duce drooling in children with disabilities or brain
damage. Scopolamine is an antimuscarinic drug,
with effects similar to those of atropine. Scopol-
amine is derived from an alkaloid of belladonna
(Atropa belladonna, commonly known as deadly
nightshade), and it works by depressing the action
of the nerve fibers near the vomiting center of the
brain and central nervous system. In therapeutic
doses, it antagonizes acetylcholine at muscarinic
receptors, but in high doses, it can also antagonize
nicotinic receptors. The lethal dose of scopolamine
has been reported to be ≥ 2–4 mg.4 The plaster
contains a reservoir of 1.5 mg of scopolamine
programmed to deliver 0.5 mg over a 3-day period.
A priming dose (140 μg) is incorporated into the
adhesive layer to saturate certain binding sites
within the skin and to accelerate the achievement
of steady-state blood levels. The remainder is re-
leased at a constant rate of approximately 5 μg per
hour. The scopolamine patch attains that con-
centration after 6 hours and a steady state of about
100 pg/mL is achieved 8–12 hours after applica-
tion.5 In this pediatric case, he was treated with
scopolamine patches over both postauricular
areas and received repeated applications of plas-
ters one day later. Due to his acute confusional
state and the clinical manifestations of anticholin-
ergic effects, scopolamine intoxication is highly
suspected.
Common complications or side effects from
scopolamine include, but are not limited to: con-
fusion, hallucination, fatigue, short-term memory
loss, difficulty with urination, blurred vision, skin
redness, and changes in heart rate.6 Reduced ac-
commodation, nearsightedness, and strabismus
are the common visual side effects from trans-
dermal scopolamine.7 The phrase “red as a beet,
hot as a hare, dry as a bone, blind as a bat, mad
as a hatter” can be used to describe a person with
anticholinergic intoxication.8 This represents the
flushed skin, hyperthermia, dry mucous mem-
branes, blurred vision, and confusion or delir-
ium that a patient may manifest. Adverse effects
were not correlated with plasma scopolamine
concentrations.
Most cases of scopolamine intoxication can be
treated by discontinuing the offending drug and
providing them with supportive care to reduce
fever, cool the patient, and maintain hydration.
Benzodiazepines can be used to decrease the pa-
tients’ agitation and restlessness. For patients who
experience toxic psychosis for up to 48 hours and
pose a danger to both themselves and others, it
may be necessary to hospitalize these patients for
close observation and management.9 In previously
reported cases, most patients were treated with
supportive care and benzodiazepines and recovery
typically occurred within 24–48 hours. However,
in our case, the patient completely recovered after
about 96–120 hours. This may be due to the
younger age of our patient and higher dosage of
scopolamine absorbed. The serum level of sco-
polamine was not measured due to laboratory
limitations. Physostigmine, an acetylcholinester-
ase inhibitor, is reserved for patients with serious
anticholinergic-induced agitation, delirium, and
hallucinations.10,11 A test dose of physostigmine,
usually 0.5 or 1 mg, administered intramuscularly,
subcutaneously, or intravenously may be given
while the patient is observed.12,13 The patients’
vital signs should be monitored for possible 
arrhythmias or hypotension from physostigmine-
induced cholinergic crisis. Relative contraindica-
tions to physostigmine administration such as
renal hypertension, hyperthyroidism, diabetes,
and coronary artery disease should be excluded
before this drug is prescribed.
The safety of scopolamine patches has not yet
been determined in children and the effects of
this drug may be cumulative; therefore the drug’s
use in pediatric patients is not recommended.
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Furthermore, scopolamine patches should never
be cut into pieces as cutting destroys the time-
release mechanism of the drug. The take home
message of this case is to relay information about
common agents with anticholinergic effects to
clinical practitioners and that drug-induced psy-
chosis should be considered in pediatric patients
with acute changes in behavior.
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